Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy

Nilsen, Line Brennhaug; Fangberget, Anne; Geier, Oliver; Olsen, Dag Rune; Seierstad, Therese

doi:10.3109/02841861003610184

Cited by 99 publications

(69 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, for prediction of pathologic response, the ADC parameters did not stand out as important (mean error rate 0.5). Similar results have been shown recently (34), although others report that tumors with low ADC values before NAC respond better to chemotherapy (35). The baseline ADC values in the present study were in good agreement with other results in malignant breast cancer (14).…”

Section: Discussionsupporting

confidence: 93%

Diffusion‐weighted and dynamic contrast‐enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients

Jensen¹,

Garzón²,

Heldahl³

et al. 2011

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Purpose: To use dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) MRI at 3 Tesla (T) for early evaluation of treatment effects in breast cancer patients undergoing neoadjuvant chemotherapy (NAC), and assess the reliability of DW-MRI.Materials and Methods: DW-and DCE-MRI acquisitions of 15 breast cancer patients were performed before and after one cycle of NAC. MRI tumor diameter and volume, apparent diffusion coefficient (ADC) and kinetic parameters (K trans , v e ) were derived. The reliability of ADC before NAC was assessed. Changes in MRI parameters after NAC were analyzed, and logistic regression analysis was used to find the best predictors for pathologic response. Results:The reliability for ADC values was high, with intraclass correlation coefficient of 0.84 (P ¼ 0.001). After one cycle of NAC, MRI tumor diameter (8%, P ¼ 0.005) and tumor volume (30%, P ¼ 0.008) was reduced for all patients, while ADC mean values increased (0.12 mm 2 /s, P ¼ 0.008). The best predictor for treatment response was a change in MRI tumor diameter with mean error rate of 0.167 (13% for responders, 5% for nonresponders, P ¼ 0.291).Conclusion: Changes in MRI derived tumor diameter and ADC after only one cycle of NAC could provide a valuable tool for early evaluation of treatment effects in breast cancer patients.

show abstract

Section: Discussionsupporting

confidence: 93%

Diffusion‐weighted and dynamic contrast‐enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients

Jensen¹,

Garzón²,

Heldahl³

et al. 2011

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…However, no consensus has been reached regarding the value of pretreatment ADC to predict the response to NAC. [17][18][19][20][21][22][23] It is also unclear whether this would be influenced by the tumor phenotype.…”

Section: Introductionmentioning

confidence: 97%

Role of the Apparent Diffusion Coefficient in the Prediction of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer

Bufi

Belli

Costantini

et al. 2015

Clinical Breast Cancer

View full text Add to dashboard Cite

“…Ces résultats n'ont cependant pas été retrouvés dans les cancers du sein [36] ou du col utérin [20], et des résultats discordants ont été obtenus dans les études qui ont porté sur les carcinomes épidermoïdes ORL [26,29]. Là encore, cette information inté-ressante sur le plan théorique n'en est pas encore au stade de pouvoir être exploitée cliniquement pour déterminer au mieux une stratégie thérapeutique individuelle.…”

Section: Affichage Des Résultatsunclassified

Functional imaging assessment of anti-angiogenic therapies: what is its place in 2012?

Lucidarme

2012

Oncologie

View full text Add to dashboard Cite

Functional imaging, which allows the study of the Brownian motion of water molecules (DW-MRI) or the microcirculation (DCE-MRI, functional CT or contrast-enhanced ultrasound), is now available in clinical practice to assess treatment efficacy in oncologic patients. These techniques are mainly used in animal model studies and in phase I clinical trials. Indeed, they lead to a better understanding of the cascade of events that occur on the vascular bed and in the tissue structure during targeted or non-targeted therapies. DW-MRI provides indirect information about the structure and particularly the cellularity of the tissue. Perfusion imaging gives information about local blood volume, blood flow, and about the transfers between intra-and extravascular spaces. However, the spread of functional imaging in everyday oncology practice as support of a treatment decision still needs additional validation and standardization efforts.

show abstract

Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy

Abstract: Pretreatment tumor ADC does not predict treatment response for patients with LABC undergoing NACT. Furthermore, ADC increase observed mid-way in the course of NACT does not correlate with tumor volume changes.

Cited by 99 publications

References 24 publications

Diffusion‐weighted and dynamic contrast‐enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients

Diffusion‐weighted and dynamic contrast‐enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients

Role of the Apparent Diffusion Coefficient in the Prediction of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer

Functional imaging assessment of anti-angiogenic therapies: what is its place in 2012?

Contact Info

Product

Resources

About